Adalimumab

證據等級: L5

預測適應症: 6 個

taiwan_regulatory.licenses is empty and original_indications is empty, so the evidence pack contains no sourced original-indication text. Per the prompt's fallback rule for missing MOA data, I've applied the same logic here: Adalimumab's original indication (rheumatoid arthritis) is stated as general/public drug knowledge, clearly distinguished from evidence-pack-sourced regulatory data (which shows 0 Norway licenses / not marketed).
The report focuses on predicted_indications[0] ("rheumatoid vasculitis"), consistent with the template's single-indication structure.
Adalimumab is an immunomodulator (TNF-α inhibitor), not an antineoplastic/cytotoxic agent → the Cytotoxicity section is omitted per the rules.

Adalimumab: From Rheumatoid Arthritis to Rheumatoid Vasculitis

One-Sentence Summary

Adalimumab is a TNF-α inhibitor originally used to treat rheumatoid arthritis and related inflammatory arthropathies. The TxGNN model predicts it may be effective for Rheumatoid Vasculitis, with 5 clinical trials and 20 publications currently retrieved in support of this direction, though most of the trial evidence is indirect (general RA/biologics practice-pattern studies rather than RV-specific interventional trials).

Quick Overview

Item	Content
Original Indication	Rheumatoid Arthritis (not present in evidence pack's regulatory data; based on established drug information)
Predicted New Indication	Rheumatoid Vasculitis
TxGNN Prediction Score	99.80%
Evidence Level	L3
Norway Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the evidence pack for this candidate (flagged as a High-severity data gap, DG002). Based on established drug information, adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor-alpha (TNF-α), blocking its pro-inflammatory cytokine effects. Its efficacy in rheumatoid arthritis (RA) is well established, and it is approved across multiple TNF-α-driven inflammatory arthropathies.

Rheumatoid vasculitis (RV) is one of the most severe extra-articular manifestations of RA — a systemic vasculitis affecting small-to-medium vessels that arises from the same underlying autoimmune/inflammatory process as joint disease, with TNF-α implicated in its pathogenesis alongside immune-complex deposition. Because RV occurs almost exclusively in patients with (often long-standing, seropositive) RA, a drug already proven to control RA-driven inflammation is mechanistically plausible for RV as well.

That said, the literature evidence is mixed: alongside a systematic review and case reports of adalimumab controlling RV, there are also case reports of anti-TNF therapy being associated with vasculitis-like or lupus-like events, and of RV symptoms recurring after adalimumab dose reduction. This bidirectional signal (TNF-α inhibition as both a plausible treatment and a reported trigger/precipitant of vasculitic events) is an important nuance for interpreting the TxGNN prediction and warrants careful case-by-case clinical judgment rather than a blanket efficacy assumption.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07138898	Phase 2	Not yet recruiting	80	Evaluates perioperative immunosuppressant (incl. biologic) holding strategies in rheumatology patients undergoing shoulder arthroplasty; assesses flare risk, not an RV efficacy trial
NCT01579006	N/A	Completed	184	Observational study of tocilizumab (not adalimumab) practice patterns in RA patients with inadequate DMARD response
NCT05111743	N/A	Completed	9,261	Real-world safety study of brolucizumab in wet AMD — unrelated drug/indication, likely a keyword-matched false positive
NCT02590562	N/A	Completed	808	Cross-sectional study of biological DMARD treatment patterns and RA disease characteristics in China
NCT05696106	N/A	Unknown	750,000	Large-scale study of incident immune-mediated inflammatory disease risk in patients on biologics/immunosuppressants for a single IMID

Note: None of the retrieved trials are interventional studies of adalimumab specifically for rheumatoid vasculitis; they are broader RA/biologics safety and practice-pattern studies (one appears unrelated). No dedicated RV trial for adalimumab is currently registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33058033	2021	Systematic Review	Clinical Rheumatology	Systematic review of biological therapy (including anti-TNF agents) in rheumatoid vasculitis; RV is a severe extra-articular RA manifestation requiring aggressive treatment
18799049	2008	Systematic Review	Clin Exp Rheumatol	Systematic review of 2,707 RA patients (18 vasculitis cases) comparing vasculitis occurrence with vs. without anti-TNF treatment
31491879	2019	Network Meta-Analysis (36 RCTs)	Int J Mol Sci	Compares 5 TNF inhibitors (incl. adalimumab) vs. methotrexate/placebo on radiographic joint destruction in RA — supports adalimumab's established anti-inflammatory efficacy
30773522	2019	Case Report	Internal Medicine (Tokyo)	Acute pulmonary hypertension crisis in an RV patient 8 months after adalimumab dose reduction — signals risk of RV flare on de-escalation
25133007	2014	Case Report	Case Reports in Rheumatology	Digital (RA-associated) vasculitis responded well to adalimumab in a 42-year-old patient
28123776	2017	Cohort Study	RMD Open	BSRBR-RA registry comparison of lupus-like and vasculitis-like event risk between TNFi- and nbDMARD-treated RA patients
34068884	2021	Review	J Clin Medicine	Update on treatment of RA-associated episcleritis/scleritis, an extra-articular manifestation overlapping with the RV spectrum
28719435	2018	Case Report	Am J Dermatopathology	Leukocytoclastic vasculitis with perivascular hemophagocytosis reported during adalimumab therapy for RA
36418100	2023	Case Report	Internal Medicine (Tokyo)	ANCA-associated nephritis emerging during abatacept/adalimumab therapy for RA, later attenuated by tocilizumab
19482531	2009	Case Report	Nephrologie & Therapeutique	ANCA-associated vasculitis (necrotizing glomerulonephritis) reported in an RA patient on adalimumab

Norway Market Information

Adalimumab is currently not marketed in Norway according to the available regulatory data (0 authorizations on record). No product/authorization details are available to tabulate.

Safety Considerations

Please refer to the package insert for safety information.

(All safety fields in the evidence pack — key warnings, contraindications, and drug-drug interactions — are currently unavailable. Notably, retrieval of the Norway package insert warnings/contraindications is flagged as a Blocking data gap, since it prevents an initial S1 safety assessment.)

Conclusion and Next Steps

Decision: Hold

Rationale:

A Blocking data gap exists (Norway package insert warnings/contraindications not retrieved), which by definition prevents even the initial (S1) safety assessment required before this candidate can advance.
Adalimumab is not currently marketed in Norway, and no adalimumab trial specifically targets rheumatoid vasculitis as an indication — supporting evidence is limited to one systematic review, one earlier systematic review of vasculitis events, an RCT meta-analysis on a different endpoint (joint destruction), and several case reports (some describing adalimumab controlling RV, others describing anti-TNF-associated vasculitic/autoimmune adverse events). This corresponds to Evidence Level L3, not L1/L2.

To proceed, the following is needed:

Retrieve the official Norway package insert (warnings, contraindications) to complete the S1 safety assessment (Blocking gap, DG001)
Obtain detailed mechanism-of-action reference data from DrugBank to strengthen the mechanistic rationale (High-priority gap, DG002)
Confirm the drug's original approved indication(s) and regulatory history via authoritative regulatory sources, since this evidence pack contains no sourced original-indication or licensing data
Given the mixed signal in the case-report literature (both efficacy and RV-flare/vasculitis-inducing reports), any future evaluation should specifically weigh anti-TNF-associated vasculitis risk against RV treatment benefit before considering guardrails for clinical use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.